The story of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a phenomenal success, producing billions, the exclusivity expiration and the subsequent arrival of cheaper alternatives have significantly impacted income. This poses questions about the long-term viability of analogous therapeutic developme… Read More